{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"24.7","value":"6.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"The estimated percent of participants who experienced severe chronic graft versus host disease (GVHD) was assessed by the 1994 Consensus Conference Working Criteria. Severe GVHD is defined using the Global Staging per 2014 National Institutes of Health (NIH) Consensus Criteria for chronic GVHD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction chemotherapy, then palifermin at the recommended phase 2 dose (RP2D) determined in Phase 1, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression.","id":"OG000","title":"2/Phase II Arm - Palifermin at the Recommended Phase 2 Dose"}],"paramType":"NUMBER","populationDescription":"The total number of participants analyzed for the primary outcome measure is 19 (16 enrolled on the phase 2 Arm and data/outcomes on the 3 participants from phase 1 treated at dose level 4).","reportingStatus":"POSTED","timeFrame":"60 months","title":"Phase II: Estimated Percent of Participants Who Experienced Severe Chronic Graft Versus Host Disease (GVHD)","type":"PRIMARY","unitOfMeasure":"Estimated percent of participants"}